Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters

BACKGROUND: The clinical features, survival outcomes and patterns of treatment failure of advanced non-small cell lung cancer (NSCLC) patients harboring distinct subtypes of EGFR mutations and receiving first-line EGFR tyrosine kinases inhibitor (TKIs) are not fully understood. METHODS: Consecutive...

Descripción completa

Detalles Bibliográficos
Autores principales: Zeng, Ya, Guo, Tiantian, Zhou, Yue, Zhao, Yang, Chu, Li, Chu, Xiao, Yang, Xi, Ni, Jianjiao, Zhu, Zhengfei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862369/
https://www.ncbi.nlm.nih.gov/pubmed/35189835
http://dx.doi.org/10.1186/s12885-022-09245-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8862369/
https://www.ncbi.nlm.nih.gov/pubmed/35189835
http://dx.doi.org/10.1186/s12885-022-09245-5

Ejemplares similares